<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Vanda Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/vanda-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(NVS) Novartis Launched Fanapt Into Competitive Schizophrenia Market</title>
		<link>http://www.stockbloghub.com/2010/01/12/nvs-novartis-launched-fanapt-into-competitive-schizophrenia-market/24749</link>
		<comments>http://www.stockbloghub.com/2010/01/12/nvs-novartis-launched-fanapt-into-competitive-schizophrenia-market/24749#comments</comments>
		<pubDate>Tue, 12 Jan 2010 22:48:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Vanda Pharmaceuticals Inc]]></category>
		<category><![CDATA[VNDA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24749</guid>
		<description><![CDATA[Recently, Novartis (NVS) launched Fanapt (iloperidone) in the U.S. Its twice daily tablets are for the treatment of schizophrenia in adults. Fanapt received approval from the US Food and Drug Administration (FDA) in May 2009. Clinical trials have shown that Fanapt improved symptoms in schizophrenic patients compared to a placebo therapy. The most common adverse drug reactions were dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia and weight gain. Under an agreement with Vanda Pharmaceuticals (VNDA), Novartis acquired exclusive commercialization rights to Fanapt in the U.S. and Canada in October 2009. In addition, Novartis has the rights to develop and commercialize an injectable form of the drug for these markets. Vanda will receive an upfront payment of $200 million as well as the potential to receive milestone payments ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/12/nvs-novartis-launched-fanapt-into-competitive-schizophrenia-market/24749/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

